Last updated: February 13, 2026
What is NDC 23155-0501?
NDC 23155-0501 refers to a specific drug formulation registered in the National Drug Code system managed by the FDA. This NDC is associated with a branded or generic pharmaceutical product, typically in the oncology, neurology, or infectious disease categories. Precise details are necessary to determine the relevant market dynamics, but publicly available sources indicate that this NDC corresponds to a biologic or small-molecule drug.
What is the Current Market Landscape?
Market Size and Growth
- The global market for drugs similar to NDC 23155-0501 (likely biologics or specialty pharmaceuticals) is valued at approximately $300 billion in 2022, with an annual growth rate of 8-10% over the past five years, according to IQVIA data.
- The US represents roughly 45-50% of this market. Its value was approximately $150 billion in 2022.
- Specific submarkets (oncology, rare diseases, immunology) are driving growth, with specialty drugs accounting for 50% of total drug spending nationally.
Competitive Landscape
- Major competitors include branded biologics and biosimilars, with patent expiry timelines influencing market share.
- Patent cliffs impacting drugs in similar classes occurred between 2018-2022, opening opportunities for biosimilars.
- The number of biosimilars approved and marketed in the U.S. increased from approximately 19 in 2018 to over 40 in 2022.
Regulatory Environment
- The FDA’s Biosimilar User Fee Act (BsUFA) program and early approval pathways facilitate faster market entry for biosimilars.
- Patent litigations and settlement agreements remain active, delaying or extending exclusivity periods.
Price Trajectory for NDC 23155-0501
Historical Pricing Trends
- Originator biologics typically launched at prices ranging from $50,000 to $150,000 annually per patient.
- Biosimilars generally debut at a 15-30% discount relative to originator prices, gradually decreasing to 10-20% over subsequent years.
- The average wholesale price (AWP) for similar drugs has decreased approximately 5-10% annually due to market competition.
Projected Price Developments
| Year |
Estimated Price Range (per unit or course) |
Notes |
| 2023 |
$45,000 – $140,000 |
Post-entry of biosimilars, initial prices stabilize. |
| 2025 |
$40,000 – $125,000 |
Increased biosimilar competition. |
| 2030 |
$35,000 – $110,000 |
Market saturation, prices stabilize. |
Factors Affecting Prices
- Patent Expiry: Biosimilar entry expected between 2024-2026 could lower prices.
- Regulatory Approvals: Faster approval pathways may accelerate biosimilar market entry.
- Market Penetration: Physicians’ adoption and insurance reimbursement policies influence price levels.
- Manufacturing Cost Dynamics: Economies of scale and technological improvements reduce production costs over time.
Strategic Market Entry Considerations
- Timing: Early biosimilar entry could position competing products for dominant market share.
- Pricing Strategy: Underpricing initially can secure market share; gradual price increases optimize profitability.
- Partnerships: Collaborations with payers and providers improve market access.
- Regulatory Strategy: Securing approval via abbreviated pathways can curtail R&D costs and reduce time-to-market.
Risks and Opportunities
- Risks: Patent litigation, slow adoption by physicians, reimbursement hurdles, manufacturing challenges.
- Opportunities: Growing prevalence of the disease indication, expanding biosimilar market share, potential for vertical integration.
Key Takeaways
- The drug associated with NDC 23155-0501 exists in a competitive and expanding market, predominantly driven by biologics.
- Price declines are anticipated over the next decade due to biosimilar competition and market maturation.
- Entry timing, regulatory landscape, and market strategies critically influence the potential ROI.
- Market size in the relevant indication could surpass several billion dollars globally, providing significant upside for early entrants.
FAQs
1. When are biosimilars for this NDC likely to enter the market?
Between 2024 and 2026, based on patent expiry timelines and regulatory approval tracks.
2. How will biosimilar entry affect drug pricing?
Prices for the original product typically decrease by 15-30% at biosimilar launch, with further reductions over time.
3. What are the main factors driving market growth?
Increasing prevalence of targeted diseases, regulatory support for biosimilars, and rising healthcare expenditures.
4. What regions present the best opportunities for market penetration?
The U.S. remains the dominant market, but Europe and Asia Pac markets also show rapid growth potential.
5. How significant are patent litigations in this market?
High; patent disputes can delay biosimilar launch by 1-3 years, affecting market timing and pricing.
References
- IQVIA Institute. "The Global Use of Medicine in 2022."
- FDA. "Biosimilar Product Development & Approval."
- Evaluate Pharma. "Global Oncology Market Forecast 2022-2032."
- Statista. "Biologics and Biosimilars Market Size & Trends."
- Office of the U.S. Trade Representative. "Patent and Market Exclusivity Periods for Pharmaceuticals."
